Portal de Periódicos da CAPES

A Comparison of the Aldosterone‐blocking Agents Eplerenone and Spironolactone

2009; Wiley; Volume: 32; Issue: 4 Linguagem: Inglês

10.1002/clc.20442

1932-8737

Asterios Karagiannis, Vasilios G. Athyros, Dimitri P. Mikhailidis,

Heart Failure Treatment and Management

Clinical CardiologyVolume 32, Issue 4 p. 230-230 Letter to the EditorFree Access A Comparison of the Aldosterone-blocking Agents Eplerenone and Spironolactone Asterios Karagiannis MD, Corresponding Author Asterios Karagiannis MD Second Propedeutic Department of Internal Medicine, Medical School, Aristotle University of Thessaloniki, Hippokration Hospital, Thessaloniki, GreeceSecond Propedeutic Department of Internal Medicine, Medical School, Aristotle University of Thessaloniki, Hippokration Hospital, Thessaloniki, GreeceSearch for more papers by this authorVasilios G. Athyros MD, Vasilios G. Athyros MD Second Propedeutic Department of Internal Medicine, Medical School, Aristotle University of Thessaloniki, Hippokration Hospital, Thessaloniki, GreeceSearch for more papers by this authorDimitri P. Mikhailidis MD, FFPM, FRCP, FRCPath, Dimitri P. Mikhailidis MD, FFPM, FRCP, FRCPath Department of Clinical Biochemistry, Vascular Prevention Clinic, Royal Free Hospital Campus, University College Medical School, University College London, London, UKSearch for more papers by this author Asterios Karagiannis MD, Corresponding Author Asterios Karagiannis MD Second Propedeutic Department of Internal Medicine, Medical School, Aristotle University of Thessaloniki, Hippokration Hospital, Thessaloniki, GreeceSecond Propedeutic Department of Internal Medicine, Medical School, Aristotle University of Thessaloniki, Hippokration Hospital, Thessaloniki, GreeceSearch for more papers by this authorVasilios G. Athyros MD, Vasilios G. Athyros MD Second Propedeutic Department of Internal Medicine, Medical School, Aristotle University of Thessaloniki, Hippokration Hospital, Thessaloniki, GreeceSearch for more papers by this authorDimitri P. Mikhailidis MD, FFPM, FRCP, FRCPath, Dimitri P. Mikhailidis MD, FFPM, FRCP, FRCPath Department of Clinical Biochemistry, Vascular Prevention Clinic, Royal Free Hospital Campus, University College Medical School, University College London, London, UKSearch for more papers by this author First published: 07 April 2009 https://doi.org/10.1002/clc.20442Citations: 3AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat No abstract is available for this article. References 1 Struthers A, Krum H, Williams GH. A comparison of the aldosterone-blocking agents eplerenone and spironolactone. Clin Cardiol. 2008; 31: 153–158. 2 Karagiannis A, Tziomalos K, Papageorgiou A, Kakafika AI, Pagourelias ED, et al. Spironolactone versus eplerenone for the treatment of idiopathic hyperaldosteronism. Expert Opin Pharmacother. 2008; 9: 509–515. 3 Ménard J. The 45-year story of the development of an anti-aldosterone more specific than spironolactone. Mol Cell Endocrinol. 2004; 217: 45–52. Citing Literature Volume32, Issue4April 2009Pages 230-230 ReferencesRelatedInformation